Literature DB >> 14500299

Does the use of a specialised paediatric retrieval service result in the loss of vital stabilisation skills among referring hospital staff?

P Ramnarayan1, J Britto, A Tanna, D Thomas, S Alexander, P Habibi.   

Abstract

AIMS: To compare the proportion of airway and vascular access procedures performed by referring hospital staff on critically ill children in two discrete time periods, before and after widespread use of a specialised paediatric retrieval service.
METHODS: Transport data were obtained from retrieval logs of all children for whom a paediatric retrieval team was launched in each of two time periods (October 1993 to September 1994; and October 2000 to September 2001).
RESULTS: The overall intubation rate was similar in the first and second time periods (83.9% v 79.1%). However, 31/51 (61%) retrieved children were intubated by referring hospital staff in 1993-94, compared to 227/269 (84%) in 2000-01. Referring hospital staff gained central venous access in 11% v 18% and arterial access in 22% v 19% of retrieved children in the first and second time periods respectively. This was in spite of a significant reduction in the proportion of children on whom these procedures were performed.
CONCLUSION: Referring hospital staff are performing a greater proportion of initial airway and vascular access procedures undertaken in the stabilisation of sick children retrieved by a specialised paediatric retrieval team. The provision of this service has not resulted in the loss of vital skills at the local hospital.

Entities:  

Mesh:

Year:  2003        PMID: 14500299      PMCID: PMC1719337          DOI: 10.1136/adc.88.10.851

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

1.  A regionalised transport service, the way ahead?

Authors:  A Rashid; T Bhuta; A Berry
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

2.  The Sheffield experiment: the effects of centralising accident and emergency services in a large urban setting.

Authors:  A N Simpson; J Wardrope; D Burke
Journal:  Emerg Med J       Date:  2001-05       Impact factor: 2.740

3.  Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery.

Authors:  R Booy; P Habibi; S Nadel; C de Munter; J Britto; A Morrison; M Levin
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

4.  The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.

Authors:  Frank Rauch; Rose Travers; Horacio Plotkin; Francis H Glorieux
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

5.  Centralization of paediatric intensive care: are critically ill children appropriately referred to a regional centre?

Authors:  A Y Goh; Q Mok
Journal:  Intensive Care Med       Date:  2001-04       Impact factor: 17.440

6.  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.

Authors:  E Aström; S Söderhäll
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

7.  Improved outcomes from tertiary center pediatric intensive care: a statewide comparison of tertiary and nontertiary care facilities.

Authors:  M M Pollack; S R Alexander; N Clarke; U E Ruttimann; H M Tesselaar; A C Bachulis
Journal:  Crit Care Med       Date:  1991-02       Impact factor: 7.598

8.  Reduction of morbidity in interhospital transport by specialized pediatric staff.

Authors:  W E Edge; R K Kanter; C G Weigle; R F Walsh
Journal:  Crit Care Med       Date:  1994-07       Impact factor: 7.598

Review 9.  Guidelines for stabilizing the condition of the critically ill child before transfer to a tertiary care facility.

Authors:  J B Kronick; N Kissoon; T C Frewen
Journal:  CMAJ       Date:  1988-08-01       Impact factor: 8.262

10.  Adverse events occurring during interhospital transfer of the critically ill.

Authors:  P W Barry; C Ralston
Journal:  Arch Dis Child       Date:  1994-07       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.